Literature DB >> 11454675

Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer.

S Matsuoka1, T Nakagawa, A Masuda, N Haruki, S J Elledge, T Takahashi.   

Abstract

The checkpoint kinase Chk2 is phosphorylated and activated in response to DNA damage such as ionizing radiation. Recently, we found a somatic mutation of CHK2 with clear loss of the wild-type allele in human lung cancer. Here we show that the mutant Chk2 exhibits modestly reduced in vitro kinase activity compared with wild type, whereas it is normally phosphorylated and activated after ionizing radiation. Interestingly, this mutant Chk2 protein was found to be less stable than wild type and could be expressed in various cell types only at a significantly reduced (20%) level of wild type. These findings confirm that the DNA damage checkpoint pathway involving CHK2 is indeed inactivated in this fatal adult cancer and also suggest that reduced expression of Chk2 may also be an important inactivating mechanism, contributing to the development of lung cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454675

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  The Role of E3 Ligase Pirh2 in Disease.

Authors:  Alexandra Daks; Olga Fedorova; Sergey Parfenyev; Ivan Nevzorov; Oleg Shuvalov; Nickolai A Barlev
Journal:  Cells       Date:  2022-04-30       Impact factor: 7.666

2.  Mutations in CHEK2 associated with prostate cancer risk.

Authors:  Xiangyang Dong; Liang Wang; Ken Taniguchi; Xianshu Wang; Julie M Cunningham; Shannon K McDonnell; Chiping Qian; Angela F Marks; Susan L Slager; Brett J Peterson; David I Smith; John C Cheville; Michael L Blute; Steve J Jacobsen; Daniel J Schaid; Donald J Tindall; Stephen N Thibodeau; Wanguo Liu
Journal:  Am J Hum Genet       Date:  2003-01-17       Impact factor: 11.025

Review 3.  The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer.

Authors:  Huy Q Ta; Daniel Gioeli
Journal:  Endocr Relat Cancer       Date:  2014-08-05       Impact factor: 5.678

4.  Alterations of Chk1 and Chk2 expression in colon cancer.

Authors:  Magdalena Stawinska; Adam Cygankiewicz; Radzislaw Trzcinski; Michal Mik; Adam Dziki; Wanda M Krajewska
Journal:  Int J Colorectal Dis       Date:  2008-08-05       Impact factor: 2.571

5.  Interdependent phosphorylation within the kinase domain T-loop Regulates CHK2 activity.

Authors:  Xin Guo; Michael D Ward; Jessica B Tiedebohl; Yvonne M Oden; Julius O Nyalwidhe; O John Semmes
Journal:  J Biol Chem       Date:  2010-08-16       Impact factor: 5.157

6.  The E3 ligase PIRH2 polyubiquitylates CHK2 and regulates its turnover.

Authors:  M Bohgaki; A Hakem; M J Halaby; T Bohgaki; Q Li; P A Bissey; J Shloush; T Kislinger; O Sanchez; Y Sheng; R Hakem
Journal:  Cell Death Differ       Date:  2013-03-01       Impact factor: 15.828

7.  DNA damage during reoxygenation elicits a Chk2-dependent checkpoint response.

Authors:  Rachel A Freiberg; Ester M Hammond; Mary Jo Dorie; Scott M Welford; Amato J Giaccia
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

8.  Limiting amounts of budding yeast Rad53 S-phase checkpoint activity results in increased resistance to DNA alkylation damage.

Authors:  Violeta Cordón-Preciado; Sandra Ufano; Avelino Bueno
Journal:  Nucleic Acids Res       Date:  2006-10-24       Impact factor: 16.971

9.  Kinesin light chain 4 as a new target for lung cancer chemoresistance via targeted inhibition of checkpoint kinases in the DNA repair network.

Authors:  Eun Ho Kim; Sang-Gu Hwang; Jeong-Hwa Baek; Hong Shik Yun; Ju-Young Kim; Janet Lee; Yeon-Joo Lee; Chang-Woo Lee; Jie-Young Song; Jiyeon Ahn; Jong Kuk Park; Jae-Sung Kim; Kee-Ho Lee
Journal:  Cell Death Dis       Date:  2020-05-26       Impact factor: 8.469

10.  Transient induction of telomerase expression mediates senescence and reduces tumorigenesis in primary fibroblasts.

Authors:  Linlin Sun; Jeffrey Y Chiang; Ji Young Choi; Zheng-Mei Xiong; Xiaojing Mao; Francis S Collins; Richard J Hodes; Kan Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-03       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.